

BENZODIAZEPINE - completare indicații ^

^nerevizuit

1) Sevrajul la alcool (1, 2, 3, 4, 5, 6, 7, 35, 36, 37).

2) Schizofrenie (8, 9, 10, 11, 12, 13, 14, 35) : - adjuvante in managementul agitatiei/agresivitatii, anxietatii, insomniei, akatisiei; catatonie.

*mentionate: lorazepam, clonazepam, diazepam, alprazolam.

3) Tulburarea afectiva bipolară (15, 16, 17, 18, 19, 20, 21, 22, 23, 35, 36, 37): - adjuvante in Episodul maniacal, mixt, managementul agitatiei, insomniei; tulburari de anxietate sau anxietatea-simptom comorbide (17, 19, 23); catatonie.

*mentionate: lorazepam, clonazepam, diazepam.

3) Tulburari de anxietate (24, 25, 26, 27, 28, 35, 36, 37):

- Tulburarea de panica (24, 25, 26, 27, 35, 37): alprazolam (FDA), clonazepam (FDA)

*mentionate: diazepam, lorazepam.

- Fobie specifica (25, 28).

- Tulburarea de anxietate sociala (25, 35, 37)

*mentionate: clonazepam, alprazolam, bromazepam.

- Tulburarea de anxietate generalizata (25, 27, 28, 35, 37)

*mentionate: alprazolam, bromazepam, diazepam, lorazepam.

4) Depresia monopolară (27, 29, 30, 31, 32, 33, 35,): adjuvante; managementul anxietatii, insomniei proeminente; tulburari de anxietate comorbide sau anxietatea-simptom (29, 34) ; catatonie.

*mentionate: lorazepam, clonazepam, diazepam.

5) Insomnie (35, 36, 37).

Referinte:

1. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder, American Psychiatric Association Publishing, updated January 2018.

2. The Management of Substance Use Disorders Work Group, VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders, Version 3.0, 2015.

3. NICE – National Institute for Health and Care Excellence, Alcohol-use disorders: diagnosis and management of physical complications, Clinical guideline, Published: 2 June 2010 nice.org.uk/guidance/cg100.

4. NICE – National Institute for Health and Care Excellence, Alcohol-use disorders: diagnosis assessment and management of harmful drinking and alcohol dependence, 2011 nice.org.uk/guidance/cg115.

5. Lingford-Hughes et al., BAP Guidelines, BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP, Journal of Psychopharmacology 0(0) 1– 54.

6. Mésusage de l'alcool dépistage, diagnostic et traitement, Recommandation de bonne pratique, Société Française d'Alcoologie – SFA, Association Nationale de Prévention en Alcoologie et Addictologie, European Federation of Addiction Societies, Alcoologie et Addictologie . 2015 ; 37 (1) : 5-84, sfalcoologie.asso.fr anpaa.asso.fr eufas.net
7. Michael Soyka, Henry R. Kranzler, Victor Hesselbrock, Siegfried Kasper, Jochen Mutschler, Hans-Jürgen Möller & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders (2017) Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision, The World Journal of Biological Psychiatry, 18:2, 86-119, DOI: 10.1080/15622975.2016.1246752.
8. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition, 2004.
9. Haute Autorité de santé, GUIDE - AFFECTION DE LONGUE DURÉE , SCHIZOPHRÉNIES Juin 2007, www.has-sante.fr.
10. Galletly et al., Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders, Australian and New Zealand Journal of Psychiatry 2016, Vol. 50(5) 1-117.
11. German society for psychiatry and psychotherapy, Psychosomatics and Neurology/DGPPN Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde S3 Treatment Guideline Schizophrenia (2006)/ S3-Behandlungsleitlinie Schizophrenie (2006).
12. Working Group of the Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. Mental Health Forum, coordination. Clinical Practice Guideline for Schizophrenia and Incipient Psychotic Disorder. Madrid: Quality Plan for the National Health System of the Ministry of Health and Consumer Affairs. Agency for Health Technology Assessment and Research, 2009. Clinical Practice Guideline: CAHTA. Number 2006/05-2.
13. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
14. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.
15. The American Psychiatric Association, Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, 2002.
16. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
17. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
18. Goodwin et al., BAP Guidelines, Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology 2016, Vol. 30(6) 495 –553.
19. Malhi et al., Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders, Australian and New Zealand Journal of Psychiatry 2015, Vol. 49(12) 1-185.

20. German society for psychiatry and psychotherapy, Psychosomatics and Neurology, S3 Guideline for the diagnosis and treatment of bipolar disorders Long Version, 2012/ DGPPN S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen Langversion, 2012.
21. Scottish Intercollegiate Guidelines Network, Bipolar affective disorder A national clinical guideline, May 2005, www.sign.ac.uk.
22. Fountoulakis K.N. et al., The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines, International Journal of Neuropsychopharmacology (2017) 20(2): 180–195.
23. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania.
24. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Panic Disorder, 2009.
25. Katzman et al., Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders, BMC Psychiatry 2014, 14(Suppl 1):S1.
26. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia, Australian and New Zealand Journal of Psychiatry 2003; 37:641–656.
27. Bon Usage des Medicaments Antidepressifs dans le Traitement des Troubles Dépressifs et des Troubles Anxieux de L'Adulte, Argumentaire, Agence Française de Sécurité Sanitaire des Produits de Santé, octobre 2006, www.afssaps.sante.fr
28. Bandelow et al., WFSBP Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care, International Journal of Psychiatry in Clinical Practice, 2012; 16: 77–84.
29. The American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd ed November 2010.
30. Canadian Network for Mood and Anxiety Treatments (CANMAT) Guidelines for the management of adults with major depressive disorder, The Canadian Journal of Psychiatry / La Revue Canadienne de Psychiatrie 2016, Vol. 61(9) 504-505.
31. Bon Usage des Medicaments Antidepressifs dans le Traitement des Troubles Dépressifs et des Troubles Anxieux de L'Adulte, Recommandations, Agence Française de Sécurité Sanitaire des Produits de Santé, octobre 2006, www.afssaps.sante.fr
32. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015.
33. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care 2007.
34. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders, 2013.
35. Baldwin et al., Joint Report from a Working Group drawn from the Royal College of Psychiatrists Psychopharmacology Special Interest Group and the British Association for Psychopharmacology, Benzodiazepines: Risks and benefits. A reconsideration, Journal of Psychopharmacology 27(11) 967 –971, 2013.
36. The College of Psychiatry of Ireland, A consensus statement on the use of Benzodiazepines in specialist mental health services, EAP03/2012 Position Paper.

37. Prescribing drugs of dependence in general practice, Part B – Benzodiazepines.
Melbourne: The Royal Australian College of General Practitioners, 2015. www.racgp.org.au